ALX Oncology Holdings Inc — balance (NASDAQ:ALXO) | MetaTrader

Ver el calendario completo

Financials

Visión general Informes Estadísticas

Activos totales 436.05 M380.18 M306.49 M242.55 M147.78 M59.05 M Total de pasivos 6.21 M17.13 M43.02 M52.84 M34.16 M33.06 M Capital total 429.85 M363.05 M263.46 M189.71 M113.62 M25.98 M Total de pasivos y patrimonio neto 436.05 M380.18 M306.49 M242.55 M147.78 M59.05 M Deuda total 5.42 M—9.68 M10.37 M10.87 M10.71 M Deuda neta -428.8 M—-256.53 M-172.37 M-116.89 M-34.08 M

Noticias

ALX Oncology nombra a Jeff Knight director de desarrollo

Wells Fargo inicia cobertura de ALX Oncology con calificación sobreponderada

ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA

CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data

IBRX Stock Jumps on Progress in NK Cell Therapy Production

JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study

RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study

RLMD Stock Surges 42% in a Week: Here's What You Should Know

GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma

EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y

Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study

LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?